BiOMViS

BiOMViS is a private, preclinical-stage biotech company developing a novel vaccine platform for infectious diseases and oncology. The company's technology centers on using reprogrammed E. coli as living factories to produce engineered Outer Membrane Vesicles (OMVs), aiming to create potent and safe vaccines. Founded and led by the Grandi family with a strong scientific advisory board, BiOMViS operates from the Toscana Life Sciences Scientific Park in Siena, leveraging its infrastructure for research and development. The company is currently pre-revenue and focused on advancing its platform and pipeline candidates.

Proprietary vaccine platform using genetically reprogrammed, non-pathogenic E. coli strains as living factories to produce engineered Outer Membrane Vesicles (OMVs). The platform utilizes precision engineering expression vectors to load OMVs with high quantities of target antigens, aiming to elicit potent and specific immune responses for prophylaxis and immunotherapy.

BiOMViS competes in the highly competitive vaccine and immuno-oncology sectors against large pharma, biotech firms using mRNA, viral vector, and other adjuvant platforms. Its differentiation lies in its engineered OMV approach, but it must demonstrate superior efficacy, safety, or manufacturing advantages to gain traction.